Core H: Neuroimaging Core

摘要：神经成像核心 活体神经成像评估大脑的结构、功能和新陈代谢提供了强大的 与分子生物标志物数据相辅相成的机械数据。神经成像的核心任务是支持 通过降低研究人员获得广泛的神经成像能力的门槛，进行了新的研究。这个 神经成像核心通过提供初始研究概念化和 设计、采集和分析协议，并协助数据解释、手稿和赠款 申请。神经成像核心还开发了积极部署的新成像方法 通过ADRC网络进行多点临床试验。核心人才是下一代科学家的导师 并协助来自其他领域的知名研究人员启动对阿尔茨海默病、衰老和神经退化的研究。 神经成像核心管理来自临床队列和研究人员的可共享图像的数据集- 启动研究并将摘要数据发送到数据管理和统计核心，以便添加到 策划临床(临床核心)、遗传和生物标记物(生物标记物核心)和组织学(神经病理学 核心)数据库，与研究人员共享，以促进进一步研究。在目前的资助期间 周期，这些努力已导致与26名知名调查人员和9名K奖获得者合作，并 支持73个资助项目，形成39份同行评议的手稿。 在下一个周期，我们将继续这些努力，并增加两个新的能力。神经血管成像将 允许探索导致AD和神经退行性变的血管机制，增加了一个新的 将“V”型生物标志物成像为ATN(MV)。深入的表型分析将从富人那里产生新的可检验的假说 综合临床、遗传、行为、生物标志物和成像数据，我们的ADRC从我们的 临床队列。我们提出了三个与国家阿尔茨海默氏症项目ACT(NAPA)主题相一致的目标： 目的1.支持现有和未来研究人员在阿尔茨海默病和衰老研究中的成像工作。这个 神经成像核心将支持新研究的设计和实施，提供安全、可访问的图像 存储、标准化分析管道，以及将成像应用于ADRD的培训。我们将提供标准 基于图像的ATN表型数据用于临床队列的病因诊断。我们将推广使用 统一成像采集，以增加调查人员与扫描等网络之间的数据共享 和ADNI。 目的2.为AD和衰老研究开发新的成像技术。神经成像核心将 开发新的成像采集和分析技术，并通过建立 神经血管成像和深层表型作为KU ADRC的新功能。 目标3.在本地和跨ADC网络共享和实施成像方法和数据。这个 神经成像核心将积极分享集成的成像数据、深度表型鉴定能力和其他新颖的 方法跨越ADRC网络，支持从临床前到多个地点的全方位临床试验。

ABSTRACT: NEUROIMAGING CORE In vivo neuroimaging assessment of brain structure, function, and metabolism provides powerful mechanistic data complementary to molecular biomarker data. The Neuroimaging Core mission is to support novel research by lowering the barriers for investigators to a wide array of neuroimaging capabilities. The Neuroimaging Core facilitates the use of MRI and PET imaging by providing initial study conceptualization and design, acquisition and analysis protocols, and assistance with data interpretation, manuscripts, and grant applications. The Neuroimaging Core also develops novel imaging methods which are actively deployed across the ADRC network in multisite clinical trials. Core personnel mentor the next generation of scientists and assist established investigators from other fields to initiate studies into AD, aging, and neurodegeneration. The Neuroimaging Core curates a dataset of shareable images from the Clinical Cohort and investigator- initiated studies and sends summary data to the Data Management and Statistics Core for addition to the curated clinical (Clinical Core), genetic and biomarker (Biomarker Core), and histological (Neuropathology Core) database which is shared with investigators for stimulating further study. During the current funding cycle, these efforts have resulted in collaborations with 26 established investigators and nine K-awardees and support for 73 funded projects resulting in 39 peer-reviewed manuscripts. In the next cycle, we will continue these efforts and add two novel capabilities. Neurovascular imaging will allow explorations of the vascular mechanisms contributing to AD and neurodegeneration, adding a novel imaging “V” biomarker to ATN(MV). Deep phenotyping will yield novel testable hypotheses from the rich integrated clinical, genetic, behavioral, biomarker and imaging data that our ADRC is accumulating from our Clinical Cohort. We propose three aims aligned with the National Alzheimer's Project ACT (NAPA) themes: Aim 1. Support imaging efforts of existing and future investigators in AD and aging research. The Neuroimaging Core will support design and implementation of new studies, provide secure, accessible image storage, standardized analysis pipelines, and training to apply imaging to ADRD. We will provide standard image-based ATN phenotype data for etiologic diagnosis of the Clinical Cohort. We will promote the use of harmonized imaging acquisitions to increase data sharing between investigators and networks such as SCAN and ADNI. Aim 2. Develop novel imaging techniques for AD and aging research. The Neuroimaging Core will develop new imaging acquisition and analysis techniques and stimulate new research by establishing neurovascular imaging and deep phenotyping as novel new capabilities in the KU ADRC. Aim 3. Share and implement imaging methods and data locally and across the ADC network. The Neuroimaging Core will actively share integrated imaging data, deep phenotyping capabilities, and other novel methods across the ADRC network in support of the full spectrum of preclinical to multisite clinical trials.